About the role
About Us
About the Role
As the Head of Global Medical Affairs you will play a critical role in shaping and executing the medical strategy across our pipeline, including two pivotal Phase III global programs.
Ideally, you will bring deep expertise in rare diseases and autoimmunology, a strong track record of leadership in medical affairs, and a passion for advancing transformative therapies for patients with high unmet medical needs. Day to day you will work across functions aligning with our Clinical Development teams to support current and future clinical programs as we approach commercialization.
This is an exciting opportunity to lead a high-impact medical affairs function at a pivotal stage of growth, shaping strategy from late-stage development through commercialization.
We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives. We are open to you working remotely.
Key Responsibilities
- Strategic Leadership:
- Develop and execute the global medical affairs strategy aligned with corporate and clinical development goals.
- Serve as a key member of the executive leadership team, contributing to overall corporate strategy and decision-making.
- Medical Affairs Execution:
- Lead the development of scientific communication plans, medical education, and publication strategies.
- Oversee global KOL engagement, advisory boards, and congress planning.
- Ensure timely and effective support for clinical development, regulatory submissions, and commercial launch readiness.
- Cross-Functional Collaboration:
- Partner closely with Clinical Development, Regulatory Affairs, Commercial, and Market Access teams.
- Provide medical insights to inform lifecycle management, label expansion, and post-marketing commitments.
- Team Building & Leadership:
- Build and lead a high-performing global medical affairs team.
- Foster a culture of scientific excellence, compliance, and patient-centricity.
- Compliance & Governance:
- Ensure all medical affairs activities are conducted in accordance with applicable laws, regulations, and industry standards.
Experience
- MD required
- Minimum 15 years of experience in the biopharmaceutical industry, with at least 8 years in medical affairs leadership roles.
- Proven experience supporting global Phase III programs and product launches.
- Deep therapeutic expertise in rare diseases and/or autoimmunology is essential.
- Demonstrated ability to build and scale medical affairs functions in a fast-paced, innovative environment.
- Strong leadership, communication, and stakeholder management skills.
- Global experience and ability to operate effectively across geographies and cultures.
Aplyr's read
Dianthus Therapeutics is a biotechnology firm pioneering treatments for autoimmune diseases, ideal for professionals passionate about cutting-edge medical innovations.
What's promising
- •Dianthus focuses on unmet needs in autoimmune diseases, offering significant potential for impactful therapies.
- •Recent hires in senior roles suggest growth and expansion in clinical development and regulatory affairs.
- •Innovative pipeline could lead to breakthroughs in treating serious conditions, attracting talent interested in pioneering research.
What to watch
- •Biotechnology sector's high-risk nature may lead to uncertain outcomes in drug development.
- •Limited public information about financial stability and long-term sustainability.
- •Potential regulatory challenges could delay product approvals and market entry.
Why Dianthus Therapeutics
- •Specializes in autoimmune diseases, a niche with significant unmet medical needs.
- •Emphasis on pharmacovigilance and clinical quality assurance highlights commitment to patient safety.
- •Leadership roles suggest a strategic focus on robust clinical and regulatory frameworks.
Aplyr’s read is generated by AI from public sources. Was it useful?
About Dianthus Therapeutics
Dianthus Therapeutics is a biotechnology company focused on developing innovative therapies for patients with autoimmune diseases and other serious conditions.
